These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 29776887)

  • 1. Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study.
    Calvo-Alén J; Vela P; Bustabad S; Maceiras F; Carmona L; Cea-Calvo L
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):116-119. PubMed ID: 29776887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
    Calvo-Alén J; Monteagudo I; Salvador G; Vázquez-Rodríguez TR; Tovar-Beltrán JV; Vela P; Maceiras F; Bustabad S; Román-Ivorra JA; Díaz-Miguel C; Rosas J; Raya E; Carmona L; Cea-Calvo L; Arteaga MJ; Fernández S; Marras C
    Clin Exp Rheumatol; 2017; 35(3):423-430. PubMed ID: 28032846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern.
    Cea-Calvo L; Raya E; Marras C; Salman-Monte TC; Ortiz A; Salvador G; Monteagudo I; Carmona L; Fernandez S; Arteaga MJ; Calvo-Allén J
    Rheumatol Int; 2018 Sep; 38(9):1735-1740. PubMed ID: 29959469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study.
    Marras C; Monteagudo I; Salvador G; de Toro FJ; Escudero A; Alegre-Sancho JJ; Raya E; Ortiz A; Carmona L; Mestre Y; Cea-Calvo L; Calvo-Alén J
    Rheumatol Int; 2017 Jul; 37(7):1195-1202. PubMed ID: 28516236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-year adherence and costs for biologic therapy for rheumatoid arthritis.
    Stolshek BS; Wade S; Mutebi A; De AP; Wade RL; Yeaw J
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP315-SP321. PubMed ID: 30020744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database.
    Bhoi P; Bessette L; Bell MJ; Tkaczyk C; Nantel F; Maslova K
    BMJ Open; 2017 Sep; 7(9):e015872. PubMed ID: 28928177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence of rheumatoid arthritis patients to biologic disease-modifying antirheumatic drugs: a cross-sectional study.
    Mena-Vazquez N; Manrique-Arija S; Yunquera-Romero L; Ureña-Garnica I; Rojas-Gimenez M; Domic C; Jimenez-Nuñez FG; Fernandez-Nebro A
    Rheumatol Int; 2017 Oct; 37(10):1709-1718. PubMed ID: 28631046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Medication Beliefs, Self-efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis.
    McCulley C; Katz P; Trupin L; Yelin EH; Barton JL
    J Rheumatol; 2018 Dec; 45(12):1636-1642. PubMed ID: 30219761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of rheumatoid arthritis in Turkey: a questionnaire study.
    Direskeneli H; Akkoç N; Bes C; Cakir N; Cefle A; Cobankara V; Dalkilic E; Dinc A; Ertenli I; Gul A; Hamuryudan V; Inanc M; Kalyoncu U; Karaaslan Y; Kasifoglu T; Keser G; Keskin G; Kisacik B; Kiraz S; Masatlioglu S; Onat AM; Ozbek S; Ozturk MA; Pamuk ON; Pay S; Pirildar T; Sayarlioglu M; Senel S; Senturk T; Tasan D; Terzioglu E; Yazici A; Yucel E
    Clin Exp Rheumatol; 2014; 32(4):477-83. PubMed ID: 24960289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to synthetic disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the OBSERVAR Study.
    Juan Mas A; Castañeda S; Cantero Santamaría JI; Baquero JL; Del Toro Santos FJ;
    Reumatol Clin (Engl Ed); 2019; 15(5):264-270. PubMed ID: 29289700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs.
    Otón T; Carmona L; Urruticoechea-Arana A; Calvo-Alén J; Arteaga MJ; Cea-Calvo L
    Rheumatol Int; 2019 Jun; 39(6):1077-1082. PubMed ID: 30989332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.
    Dasgupta B; Combe B; Louw I; Wollenhaupt J; Zerbini CA; Beaulieu A; Schulze-Koops H; Durez P; Wolff V; Yao R; Weng HH; Govoni M; Vastesaeger N
    Arthritis Care Res (Hoboken); 2014 Dec; 66(12):1799-807. PubMed ID: 24839031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs.
    Aaltonen KJ; Turunen JH; Sokka T; Puolakka K; Valleala H
    Clin Exp Rheumatol; 2016; 34(4):694-7. PubMed ID: 27213997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High degree of nonadherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Rauscher V; Englbrecht M; van der Heijde D; Schett G; Hueber AJ
    J Rheumatol; 2015 Mar; 42(3):386-90. PubMed ID: 25593229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Monchablon C; Gondé H; Pouplin S; Varin R; Vittecoq O; Lequerré T
    Clin Rheumatol; 2020 Jan; 39(1):207-216. PubMed ID: 31768668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims.
    Curtis JR; Schabert VF; Harrison DJ; Yeaw J; Korn JR; Quach C; Yun H; Joseph GJ; Collier DH
    Clin Ther; 2014 Jul; 36(7):996-1004. PubMed ID: 25012729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients.
    Tkacz J; Ellis L; Bolge SC; Meyer R; Brady BL; Ruetsch C
    Clin Ther; 2014 May; 36(5):737-47. PubMed ID: 24661783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.